Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of ...

Who has Zenas partnered with for thyroid eye disease programs ... with GCs has not been shown to prevent recurrence of disease. The pathogenesis of IgG4-RD suggests that B cell-targeted therapies ...

for the treatment of thyroid eye disease (TED). As China's first and the world's second approved IGF-1R antibody drug, SYCUME® has ended a 70-year drought of no new treatment option for TED in China.

Innovent Biologics’ Sycume receives China NMPA approval for treatment of thyroid eye disease: San Francisco Monday, March 17, 2025, 16:00 Hrs [IST] Innovent Biologics, Inc, a wo ...

Fibromyalgia, a disorder of as yet unclear pathophysiology ... disease and fibromyalgia. Several pathophysiologic pathways might contribute to associated conditions and symptoms when thyroid ...

These new results demonstrate the ability of LX-101 to effectively target the underlying processes that drive TED pathogenesis ... including thyroid eye disease (TED). For more information ...

("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and ...

SAN FRANCISCO and SUZHOU, China, March 14, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutic ...